According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:
1. Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) is the top general drug manufacturer stock with a Zen Score of 60, which is 20 points higher than the general drug manufacturer industry average of 40. It passed 22 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -10.26% over the past year, underperforming other general drug manufacturer stocks by -21 percentage points.
Johnson & Johnson has an average 1 year
price target of $176.88, an upside of 20.47% from Johnson & Johnson's current stock price of $146.82.
Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Johnson & Johnson, 37.5% have issued a Strong Buy rating, 25% have issued a Buy, 37.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Gilead Sciences (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) is the second best general drug manufacturer stock with a Zen Score of 56, which is 16 points higher than the general drug manufacturer industry average of 40. It passed 20 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock lose -19.01% over the past year, underperforming other general drug manufacturer stocks by -30 percentage points.
Gilead Sciences has an average 1 year
price target of $80.42, an upside of 21.95% from Gilead Sciences's current stock price of $65.94.
Gilead Sciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Gilead Sciences, 16.67% have issued a Strong Buy rating, 8.33% have issued a Buy, 75% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Astrazeneca (NASDAQ:AZN)
Astrazeneca (NASDAQ:AZN) is the third best general drug manufacturer stock with a Zen Score of 52, which is 12 points higher than the general drug manufacturer industry average of 40. It passed 19 out of 38 due diligence checks and has strong fundamentals. Astrazeneca has seen its stock return 2.69% over the past year, underperforming other general drug manufacturer stocks by -8 percentage points.
Astrazeneca has an average 1 year
price target of $83.50, an upside of 10.63% from Astrazeneca's current stock price of $75.48.
Astrazeneca stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Astrazeneca, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.